Physician profile
Jonathan Lee
NPI 1235419904
$32,273.01
in general payments reported to CMS, 2019-2025
61 companies · $6,616 in 2025
The $6,616 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,516 · 2022: $6,303 · 2023: $7,360 · 2024: $6,479 · 2025: $6,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20K · Education: $90.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20,363.13 |
| Education | $90.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $5,574.54 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,288.64 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $2,230.47 | 2021-2025 | Evenity, Repatha, Prolia |
| Abbvie INC. | $2,029.71 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,982.33 | 2021-2025 | |
| Lilly USA, LLC | $1,317.10 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $1,119.52 | 2021-2025 | Rexulti |
| Pfizer INC. | $1,045.51 | 2021-2025 | |
| Glaxosmithkline, LLC. | $987.34 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $890.83 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $881.39 | 2021-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Biohaven Pharmaceutical Holding Company LTD. | $851.95 | 2022 | |
| Exact Sciences Corporation | $689.93 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $653.61 | 2022-2025 | |
| Astellas Pharma US INC | $641.67 | 2021-2025 | Veozah, Myrbetriq |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $582.59 | 2022-2024 | Gvoke Hypopen, Keveyis |
| Axsome Therapeutics, INC. | $502.61 | 2024-2025 | Auvelity, Symbravo |
| Merck Sharp & Dohme LLC | $460.40 | 2021-2025 | Verquvo, Gardasil 9, Belsomra |
| Insulet Corporation | $452.52 | 2022-2024 | Omnipod |
| Takeda Pharmaceuticals U.S.A., INC. | $449.74 | 2021-2024 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $439.02 | 2021 | |
| Beta Bionics, INC. | $430.48 | 2023-2024 | Ilet Bionic Pancreas |
| Sanofi-Aventis U.S. LLC | $395.61 | 2021-2025 | |
| Esperion Therapeutics, INC. | $394.35 | 2021-2024 | Nexletol |
| Gilead Sciences, INC. | $388.37 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $386.71 | 2021-2025 | Spravato |
| Zealand Pharma US, INC. | $383.10 | 2021-2022 | |
| Shield Therapeutics INC | $324.16 | 2023-2025 | Accrufer |
| Cequr Corporation | $279.28 | 2025 | Cequr Simplicity |
| Upsher-Smith Laboratories LLC | $273.98 | 2021-2023 | |
| Eisai INC. | $260.99 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $254.43 | 2021-2025 | Austedo Xr, Austedo Xr |
| Sumitomo Pharma America, INC. | $250.04 | 2023-2025 | Gemtesa |
| Lundbeck LLC | $241.67 | 2024-2025 | Vyepti, Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $229.08 | 2021-2025 | Xifaxan, Trulance |
| Dexcom, INC. | $206.42 | 2021-2025 | Dexcom G6 Transmitter |
| Viiv Healthcare Company | $195.59 | 2022 | |
| Phathom Pharmaceuticals, INC. | $180.01 | 2024-2025 | Voquezna |
| Mannkind Corporation | $124.93 | 2024-2025 | |
| Amarin Pharma, INC. | $122.57 | 2021-2022 | |
| Dynavax Technologies Corporation | $110.13 | 2023-2025 | Heplisav-B |
| Arbor Pharmaceuticals, INC. | $105.58 | 2021-2022 | |
| Optinose US, INC. | $76.30 | 2024-2025 | |
| Edwards Lifesciences Corporation | $75.97 | 2023-2025 | |
| Radius Health, INC. | $69.76 | 2022-2025 | Tymlos |
| Horizon Therapeutics Plc | $54.78 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $43.78 | 2023 | |
| Stryker Corporation | $41.52 | 2021 | |
| Impel Pharmaceuticals INC. | $40.60 | 2023 | Trudhesa |
| Azurity Pharmaceuticals, INC. | $34.81 | 2023 | Edarbi |
| Kowa Pharmaceuticals America, INC. | $31.09 | 2023 | Seglentis, Livalo |
| Nevro Corp. | $27.99 | 2022-2024 | Senza |
| Phadia US INC. | $25.68 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Antares Pharma, INC. | $18.62 | 2024 | Xyosted |
| Amphastar Pharmaceuticals, INC. | $17.87 | 2024 | |
| Supernus Pharmaceuticals, INC. | $17.42 | 2021 | |
| Corcept Therapeutics | $16.48 | 2023 | Korlym |
| Sunovion Pharmaceuticals INC. | $16.28 | 2022 | |
| Ibsa Pharma INC. | $15.63 | 2024 | Licart, Flector, Tirosint |
| Daiichi Sankyo INC. | $14.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.